Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer
NCT02649686Phase 1Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- May 2016
- Primary completion
- Sep 2017
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab in breast cancer, sponsored by Canadian Cancer Trials Group. Primary endpoint: Recommended Phase II Dose at 18 months. Started May 2016; status: completed.
02
Drugs
durvalumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02649686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02649686.